Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.41 |
| ▸ | HTR2C | P28335 | 8/20 | 0.41 |
| ▸ | MAOA | P21397 | 7/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15466643 | 0.81 | MAOB (0.41) | MAOBHTR2CMAOAKDM1ACYP2C19 | |
| SCHEMBL21035178 | 0.78 | HDAC4 (0.38) | MAOBHTR2CMAOAKDM1ACYP2C19 | |
| SCHEMBL22495822 | 0.78 | HDAC4 (0.38) | MAOBHTR2CMAOAKDM1ACYP2C19 | |
| SCHEMBL16762126 | 0.78 | MAOB (0.48) | MAOBHTR2CMAOAKDM1ACYP2C19 | |
| SCHEMBL18567234 | 0.78 | MAOB (0.48) | MAOBHTR2CMAOAKDM1ACYP2C19 | |
| SCHEMBL446481 | 0.78 | MAOB (0.48) | MAOBHTR2CMAOAKDM1ACYP2C19 | |
| SCHEMBL446482 | 0.78 | MAOB (0.48) | MAOBHTR2CMAOAKDM1ACYP2C19 | |
| SCHEMBL12728259 | 0.78 | MAOB (0.48) | MAOBHTR2CMAOAKDM1ACYP2C19 | |
| SCHEMBL26244344 | 0.76 | KDM1A (0.46) | HTR2CKDM1ASLC6A2SLC6A3HTR2B | |
| SCHEMBL21035177 | 0.73 | SLC6A3 (0.41) | KDM1ASLC6A3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
| CN-111386114-A | Novel benzimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenase | 百济神州有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019101188-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES | BEIGENE, LTD. (GB) | 2019-05-31 | — | — | WO | disclosed |
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| CN-103250099-B | Norbornane-based PAC Ballast and positive-one photosensitive resin composition encompassing the PAC | PROMERUS LLC | 2015-07-22 | — | — | CN | disclosed |
| US-20130323640-A1 | Preparation of Norbornane-based PAC Ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2013-12-05 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| CN-103250099-A | Norbornane-based PAC Ballast and positive-one photosensitive resin composition encompassing the PAC | PROMERUS LLC | 2013-08-14 | — | — | CN | disclosed |
| EP-2622410-A1 | NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC | Promerus, LLC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012044719-A1 | NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC | PROMERUS LLC (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | IDO2, IDO1, TPH2 | MAOB 18/4885HTR2C 21/4885MAOA 15/4885 |
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | IDO1, IDO2, TPH2 | MAOB 15/4885HTR2C 29/4885MAOA 13/4885 |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | NBAS, PHB2, BDNF | MAOB 1418/4885HTR2C 2003/4885MAOA 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.